Sugi Predict

Sugi Predict / Compounds / SCHEMBL20804375

SCHEMBL20804375

SCHEMBL20804375

O=C(Nc1ccccc1)Nc1cc(NC(=O)Nc2ccccc2)cc(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.85
▸ TP53 P04637 1/20 0.85
▸ EPHX1 P07099 1/20 0.85
▸ TSHR P16473 1/20 0.85
▸ EPHX2 P34913 1/20 0.85
▸ CDK9 P50750 1/20 0.85
▸ CLK4 Q9HAZ1 1/20 0.85
▸ KMT2A Q03164 7/20 0.73
▸ RAB9A P51151 6/20 0.73
▸ MEN1 O00255 5/20 0.73
▸ MAPT P10636 4/20 0.73
▸ NPSR1 Q6W5P4 1/20 0.73
▸ CASP3 P42574 1/20 0.71
▸ SENP7 Q9BQF6 1/20 0.71
▸ MAOA P21397 2/20 0.68
▸ MAOB P27338 2/20 0.68
▸ SIRT1 Q96EB6 2/20 0.68
▸ NPC1 O15118 5/20 0.65
▸ TAAR1 Q96RJ0 3/20 0.65
▸ LMNA P02545 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17193484 0.93 TP53 (0.81) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL133103 0.92 SMN1; SMN2 (1.00) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL11059378 0.90 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL28431956 0.90 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL30786615 0.90 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL3037927 0.90 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL29392345 0.90 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL12644777 0.85 MAOA (0.71) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL12218114 0.85 MEN1 (1.00) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL19501805 0.83 KMT2A (0.81) SMN1; SMN2TP53EPHX1TSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230302030-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) 2023-09-28 — — US disclosed
US-20200246365-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) 2020-08-06 — — US disclosed
WO-2019046931-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200246365-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE RAN, RANBP1, GDI2 SMN1; SMN2 2668/4885TP53 1247/4885EPHX1 2387/4885
US-20230302030-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase RAN, RANBP1, GDI2 SMN1; SMN2 2668/4885TP53 1247/4885EPHX1 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.